U.S. Contraceptive Market Size & Outlook, 2024-2030
Related Markets
U.S. contraceptive market highlights
- The U.S. contraceptive market generated a revenue of USD 8,082.1 million in 2024 and is expected to reach USD 10,683.5 million by 2030.
- The U.S. market is expected to grow at a CAGR of 4.8% from 2025 to 2030.
- In terms of segment, contraceptive devices was the largest revenue generating product in 2024.
- Contraceptive Devices is the most lucrative product segment registering the fastest growth during the forecast period.
Contraceptive market data book summary
| Market revenue in 2024 | USD 8,082.1 million |
| Market revenue in 2030 | USD 10,683.5 million |
| Growth rate | 4.8% (CAGR from 2025 to 2030) |
| Largest segment | Contraceptive devices |
| Fastest growing segment | Contraceptive Devices |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Contraceptive Drugs, Contraceptive Devices |
| Key market players worldwide | Bayer AG, Cupid, Helm AG, Church & Dwight Co Inc, Organon & Co Ordinary Shares, Pfizer Inc, Viatris Inc, AbbVie Inc, Afaxys, Veru Inc, Agile Therapeutics Inc, Janssen Pharmaceuticals, China Resources Pharmaceutical Group Ltd Registered Shs Unitary 144A/Reg S, Crinetics Pharmaceuticals Inc |
Other key industry trends
- In terms of revenue, U.S. accounted for 25.9% of the global contraceptive market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. contraceptive market is projected to lead the regional market in terms of revenue in 2030.
- Mexico is the fastest growing regional market in North America and is projected to reach USD 751.0 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Contraceptive Market Scope
Contraceptive Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Crinetics Pharmaceuticals Inc | View profile | 210 | 6055 Lusk Boulevard, San Diego, CA, United States, 92121 | https://www.crinetics.com |
| China Resources Pharmaceutical Group Ltd Registered Shs Unitary 144A/Reg S | View profile | 72986 | 26 Harbour Road, 41st Floor, China Resources Building, Room 4104-05, Wanchai, Hong Kong | https://www.crpharm.com |
| Janssen Pharmaceuticals | View profile | 1-10 | Titusville, New Jersey, United States, North America | https://www.xarelto-us.com |
| Helm AG | View profile | 1001-5000 | Hamburg, Hamburg, Germany, Europe | https://www.helmag.com |
| Cupid | View profile | 51-100 | Nasik, Maharashtra, India, Asia | https://www.cupidlimited.com |
| Afaxys | View profile | 1-10 | Charleston, South Carolina, United States, North America | https://www.afaxys.com/ |
| Veru Inc | View profile | 233 | 2916 North Miami Avenue, Suite 1000, Miami, FL, United States, 33127 | https://www.verupharma.com |
| Agile Therapeutics Inc | View profile | 19 | 500 College Road East, Suite 310, Princeton, NJ, United States, 08540 | https://www.agiletherapeutics.com |
| Organon & Co Ordinary Shares | View profile | 10000 | 30 Hudson Street, Floor 33, Jersey City, NJ, United States, 07302 | https://www.organon.com |
| Viatris Inc | View profile | 38000 | 1000 Mylan Boulevard, Canonsburg, PA, United States, 15317 | https://www.viatris.com |
| Church & Dwight Co Inc | View profile | 5550 | 500 Charles Ewing Boulevard, Ewing, NJ, United States, 08628 | https://www.churchdwight.com |
| Bayer AG | View profile | 99723 | Kaiser-Wilhelm-Allee 1, Leverkusen, NW, Germany, 51368 | https://www.bayer.com |
| Pfizer Inc | View profile | 88000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | https://www.pfizer.com |
| AbbVie Inc | View profile | 50000 | 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 | http://www.abbvieinvestor.com |
U.S. contraceptive market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to contraceptive market will help companies and investors design strategic landscapes.
Contraceptive devices was the largest segment with a revenue share of 52.46% in 2024. Horizon Databook has segmented the U.S. contraceptive market based on contraceptive drugs, contraceptive devices covering the revenue growth of each sub-segment from 2018 to 2030.
The contraceptive drugs and devices market in the U.S. dominated the North America market with the largest revenue share in 2024 due to the increasing use of personalized medicine approaches in contraception, where patients choose methods custom-made to their specific health needs and lifestyle preferences.
New product launches further contribute to the growth of the market in the country. For instance, in July 2024, Femlyv is the first FDA-approved dissolvable birth control pill, designed for individuals who have difficulty swallowing tablets.
It contains norethindrone acetate and ethinyl estradiol, which have been used in swallowable forms since 1968. This new formulation aims to expand access to contraception for those facing swallowing challenges.
Reasons to subscribe to U.S. contraceptive market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. contraceptive market databook
-
Our clientele includes a mix of contraceptive market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. contraceptive market , including forecasts for subscribers. This country databook contains high-level insights into U.S. contraceptive market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. contraceptive market size, by product, 2018-2030 (US$M)
U.S. Contraceptive Market Outlook Share, 2024 & 2030 (US$M)
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
